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CALM/AF10-leukemiaThe CATS protein (also known as FAM64A and RCS1) was ﬁrst identiﬁed as a novel CALM (PICALM) interactor
that inﬂuences the subcellular localization of the leukemogenic fusion protein CALM/AF10. CATS is highly
expressed in cancer cell lines in a cell cycle dependent manner and is induced by mitogens. CATS is considered
a marker for proliferation, known to control the metaphase-to-anaphase transition during the cell division.
Using CATS as a bait in a yeast two-hybrid screen we identiﬁed the Kinase Interacting Stathmin (KIS or
UHMK1) protein as a CATS interacting partner. The interaction between CATS and KIS was conﬁrmed by GST
pull-down, co-immunopreciptation and co-localization experiments. Using kinase assay we showed that CATS
is a substrate of KIS andmapped the phosphorylation site to CATS serine 131 (S131). Protein expression analysis
revealed that KIS levels changed in a cell cycle-dependentmanner and in the opposite direction to CATS levels. In
a reporter gene assay KISwas able to enhance the transcriptional repressor activity of CATS, independent of CATS
phophorylation at S131. Moreover, we showed that CATS and KIS antagonize the transactivation capacity of
CALM/AF10.In summary, our results show that CATS interacts with and is a substrate for KIS, suggesting that
KIS regulates CATS function.
© 2013 Elsevier B.V. Open access under the Elsevier OA license.1. Introduction
The rare but recurring t(10;11)(p13;q14) translocation leads to the
fusion of CALM (PICALM) to AF10 [1]. The CALM/AF10 fusion is observed
in acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL)
and in lymphoma [2–4]. CALM/AF10 is themost frequent fusion found in
T-ALL with T-cell receptor (TCR) gamma/delta rearrangement [5–7].
The CALM/AF10 fusion gene leads to the development of leukemia in
a murine bone marrow transplantation model [8,9], and in transgenic
mice [10]. There is increasing evidence that CALM/AF10 exerts itserapy Center, State University
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evier OA license.leukemogenic potential mainly through two pathways: (i) transcrip-
tional deregulation of target genes, including the HOXA gene cluster,
therefore interfering with normal hematopoietic differentiation
[8,10–13] and (ii) through the recently described novel pathway in
which CALM/AF10 increases genomic instability through the global
reduction of histone H3K79 methylation [14,15]. To date, several
CALM/AF10 interacting proteins have been identiﬁed (e.g. CATS,
DOTL1, IKAROS, FHL2), shedding light on the molecular mechanism rel-
evant for CALM/AF10-mediated leukemogenesis and the possible in-
volvement of these proteins in the transformation process [13,16–19].
We initially identiﬁed CATS (FAM64A) in a yeast-two-hybrid
(Y2H) screen as a CALM interacting protein [16]. The CATS interaction
region of CALM was mapped to amino acids 221 to 294 of CALM
which is contained in the CALM moiety of both CALM/AF10 and the
MLL/CALM fusion proteins. The ﬁndings that expression of CATS
markedly increased the nuclear localization of CALM/AF10 [16] and
that the murine Cats transcripts were up-regulated in hematopoietic
cells (B220+ lymphoid cells) transformed by CALM/AF10 in comparison
to the same subpopulation from non-leukemic mice [8,20], suggested
that CATS may play a role in CALM/AF10-mediated transformation.
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GAL4-based transactivation assay, CATS functions as a transcriptional
repressor when fused to a heterologous DNA-binding domain
(GAL4-DBD) [16]. In normal adult tissue, CATS expression is restricted
to the lymphoid compartment; nevertheless detailed analysis of protein
expression showed high expression of CATS in leukemia, lymphoma and
tumor cell lines. The protein levels of CATS are cell cycle-dependent, in-
duced by mitogens and correlate with the proliferative state of the cell.
Thus CATS can be viewed as a marker for proliferation [20].
Satoh and colleagues identiﬁed CATS (referred as FAM64A) as one
of the 47 prion protein (PrPC) interactors [21].
Moreover, CATS has been described as the Regulator of Chromosome
Segregation, RCS1, a substrate of the anaphase-promoting complex/
cyclosome (APC/C), whose loss results in faster progression from
metaphase to anaphase and accelerated degradation of securin and
cyclin B [22].
To further elucidate CATS function we searched for CATS
interacting proteins using a Y2H approach. The Kinase Interacting
Stathmin (KIS or UHMK1) was identiﬁed as one of the several CATS
interacting partners. KIS is a nuclear serine/threonine kinase that
possesses a U2AF homology motif (UHM) and phosphorylates and
regulates the activity of RNA associated factors [23–26]. KIS positively
regulates cell cycle progression through phosphorylation and inhibition
of p27KIP1 [27]. Here we show that CATS and KIS interact in in vivo and
that CATS is a phospho-protein, which is phosphorylated at serine 131
(S131) by KIS in vitro. Our data suggest that KIS controls CATS function.
The implications of these ﬁndings for our understanding of CALM-
AF10-mediated leukemogenesis are discussed.2. Material and methods
2.1. Plasmid construction
The bait plasmid for Y2H screen was constructed by inserting CATS
cDNA into the pGBKT7 vector (Clontech, Heidelberg, Germany).
CATS expressing plasmids (pSﬁExp-CATS-HA) were constructed by
cloning the PCR-ampliﬁed CATS (both isoforms 1 and 2) in-frame with
the C-terminal HA tag of the pSﬁExpress expression vector [28]. The
CATS ORF, and deletion mutants (N-termini and central domain of
CATS, amino acids 1–143 and 136–187; respectively) were cloned into
the modiﬁed bacterial expression vector pET28a-GST-Tev [29] to be
expressed as the GST-CATS FL(1–238), GST-CATS NT(1–143) and
GST-CATS (136–187) fusion proteins.
The phospho-defective mutation S131A was introduced into the
constructs pET28a-GST-Tev-CATS NT(1-143) and pM1-CATS (the
GAL4-DBD-CATS expressing construct) [16], and phospho-mimicmuta-
tion S131D was introduced into pM1-CATS (GAL4-DBD-CATSD131)
using the QuickChange™ Site Directed Mutagenesis Kit (Stratagene, La
Jolla, CA, USA).
The pEYFP-C1-CATS and -KIS expressing plasmids were constructed
by cloning the respective PCR ampliﬁed human ORF into the pEYFP-C1
vector (Clontech). For a detailed description of the constructs contact
the authors.Fig. 1. CATS interacts with the Kinase Interacting Stathmin, KIS. (A) Diagram representing th
contains an N-terminal serine/threonine kinase domain and a C-terminal noncanonical RNA
residues 33–419 of KIS. (B) CATS and KIS interaction was tested in the Y2H system. The yeast s
(1–11) isolated in the screen. Co-transfection of GAL4-DBD-CATS and (1) GAL4-AD-KIS (aa 33–
on an synthetic drop-out plate lacking leucine, tryptophan, histidine and adenine (-L, -W, -H, -
letion mutants expressed as glutathione S-transferase (GST)-fusions. (D) Conﬁrmation of CAT
bated with His-KIS cellular extracts, washed and analyzed by SDS-PAGE (left panel). The r
mutants and GST-only control are indicated with an asterisk. (E) Co-immunoprecipitation of
were precipitated with anti-HA and anti-GFP antibodies and respective isotype controls. W
shown in the lower panels (left and right panels, respectively). WB analysis of the co-precipit
respectively. As input control, lanes 6, 7 and 8 were loaded with 5% of the protein extract used
Lysates of U937 and Jurkat cells were precipitatedwith anti-KIS 3B12 (lane 1) or isotype control
with 10% input of the reaction.2.2. Yeast two hybrid screening
The AH109 yeast strain (Clontech) was serially transformed with
the bait plasmid pGBKT7-CATS and with an HeLa S3 cDNA library
cloned in the pGADGH vector (Clontech). The resulting colonies
were plated on selective plates lacking histidine, adenine, leucine
and tryptophan and colonies exhibiting a positive beta-galactosidase
reaction were selected for further analysis.
2.3. Transfection of mammalian cells and protein extraction
1×106 HEK293 cells were transiently transfected with 8 μg of
plasmid DNA and 12 μg polyethyleneimine (PEI) (Sigma-Aldrich, St
Louis, MO, USA). After 24 h the cells were harvested, washed and
lysed with 1 ml lysis buffer [50 mM Tris–HCl pH 8, 150 mM NaCl,
0.02% sodium azide, 0.1% SDS, 1% NP-40 and 0.5% sodium deoxycholate
and protease inhibitor cocktail (Roche, Basel, Switzerland)] for 30 min
on ice. Whole-cell extracts were cleared by centrifugation.
2.4. Immunobloting and immunoﬂuorescence
Immunocomplexes and cellular lysates were electrophoresed on
10–12% SDS-PAGE and transferred to nitrocellulose membrane
(Hybond™ ECL™, GE Healthcare, Buckinghamshire, UK). The mem-
branes were blocked and probed with speciﬁc antibody, followed by
secondary antibodies conjugated to horseradish peroxidase. Proteins
were detected with ECL (Pierce, Rockford, IL, USA).
For immunoﬂuorescence, U2OS cells co-transfected with pECE-HA-
KIS [23] and pEYFP-C1-CATS were grown on coverslips, ﬁxed in 2%
paraformaldehyde for 10 min, permeabilized with PBS/0.1% Triton X
for 10 min at RT and blocked with PBS/10% FCS for 1 h. Coverslips
were incubated with rabbit polyclonal anti-HA (diluted 1:200) (ab
9110; Abcam, Cambridge, MA, USA). Secondary Cy™3-conjugated anti-
bodies diluted 1:500 were used for detection of the primary antibody.
Nuclei were counterstained with DAPI (Sigma-Aldrich), cells were
mounted on slides using Cytomat medium (DAKO, Glostrup, Denmark)
and analyzed in a confocal ﬂuorescence laser scanning system (TCS-SP2
and DM IRB inverted microscope, Leica, Germany).
2.5. Immunoprecipitation
Cellular extracts of HEK293 cells, co-transfected with GFP-KIS and
pSﬁExp-CATS-HA (500 μg) were incubated for 5 h with 5 μg rabbit
anti-HA (sc-805, Santa Cruz Biotechnology) and mouse anti-GFP
(sc-9996) (or respective isotype controls), which had been previously
incubated with 30 μl Protein A-Sepharose (GE Healthcare) for 1 h.
Beads were extensively washed with the lysis buffer (50 mM Tris–HCl
pH 8, 150 mM NaCl, 0.02% sodium azide, 0.1% SDS, 1% NP-40 and 0.5%
sodium deoxycholate), resuspended in SDS sample buffer, boiled and
separated on a 10% SDS-PAGE gel. Subsequent Western blot analysis
was carried out with anti-KIS 3B12 [24] and anti-HA antibodies. For
immunoprecipitation of the endogenous protein, 900 μg of U937
and Jurkat cellular extracts were incubated with 100 μl monoclonal
rat anti-KIS 3B12 or normal rat IgG overnight. Protein G-Sepharosee protein structure of KIS and the prey clone protein discovered in our Y2H screen. KIS
recognition motif of the UHM (U2AF homology motif) type. The prey clone codes for
train AH109 was cotransformed with the CATS bait (GAL4-DBD-CATS) and prey plasmids
419); (2–11) GAL4-AD-clones containing other preys. Interactionwas accessed for growth
A), and supplemented with X-α-GAL. (C) Diagram representing the CATS protein and de-
S-KIS interaction in vitro. Bacterially expressed (GST)-fusions of CATS (lower panel) incu-
ight panel shows the Comassie blue staining of the input. Recombinant CATS, deletion
CATS and KIS. Lysates of HEK293 overexpressing HA-tagged CATS isoforms and GFP-KIS
B analysis of the precipitation reactions with anti-HA and anti-KIS 3B12 antibodies is
ated proteins with anti-KIS 3B12 and anti-HA is shown in the upper left and right panels,
for each precipitation reaction. (F) Co-immunoprecipitation of the endogenous proteins.
antibody (lanes 2) and analyzed byWestern blotwith anti-CATS 2C4. Lanes 3were loaded
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preceded as described above. Western blot analysis was carried out
with anti-CATS 2C4 [16].
2.6. Expression of recombinant proteins in bacterial cells
Induction of GST-CATS FL(1–238), GST-CATS NT(1–143), GST-CATS
NT(1–143)S131A, GST-CATS(136–187) and GST-CATS CT(188–248) fu-
sion protein expression in Escherichia coli strain Rosetta™(DE3)pLysS
(GST-CATS FL(1–238)) (Novagen, Merck, Darmstadt, Germany) or
BL21 (DE3) pRARE (Novagen) were achieved with 1 mM IPTG for 2 h
at 37 °C. Cells were lysed by sonicating for 30 s in GSB buffer (25 mM
potassium Hepes pH 7.5, 0.3 m KCl, 1 mm EDTA, 0.1% NP-40, 10%
glycerol) and 1× protease inhibitor cocktail (Roche). Recombinant pro-
teinswere puriﬁedwith glutathione Sepharose 4B beads (GEHealthcare).
2.7. GST pull-down
About 200 μl of cellular extract of HEK293 cells, transfected with
pcDNAHis-KIS, [27] was incubated with 25 μl of immobilized GST-CATS
fusion proteins orGST for 4 h at 4 °C. After extensivewasheswith binding
buffer, beads were resuspended in SDS sample buffer, boiled and sepa-
rated on a 10% SDS-PAGE gel. Subsequent Western blot analysis was
carried out with Penta-His (Qiagen, Hilden, Germany) and anti-GST
(sc-459, Santa Cruz Biotechnology) antibodies.
2.8. Phosphorylation reactions
GST-KIS kinase or GST-KISK54R dead kinase control was used in
phosphorylation reactions as previously described [23] with the indi-
cated puriﬁed CATS substrates. Phosphopeptide mapping reactions
were carried out with 500 μM of the indicated synthetic peptides (PSL
GmbH, Heidelberg, Germany), and 0.1 mM [γ-32P]ATP for 150 min at
30 °C. Phosphate incorporation was measured by spotting the reactionA
YFP-CATS 
HA-KIS(Cy3) 
Merg
 DAP
Fig. 2. Subcellular localization of CATS and KIS. Confocal images of U2OS cells transiently transf
nucleus: Channels are indicated above the images (DAPI, YFP, Cy3 and merged). (B) Confocal l
three YFP (CATS), Cy3 (KIS) and DAPI channels merged. The graph shows YFP (CATS), Cy3 (KISonto 2-cm2 pieces of P81 phosphocellulose paper (Whatman®), which
were washed with 75 nM phosphoric acid, then with water, dried and
exposed to phosphorimaging.2.9. Reporter gene assay
HEK293 cells were seeded in 24 well plates and co-transfected with
100 ng of the pGAL45tk-LUC reporter plasmid [30], 20 ng of pRL-null
co-reporter plasmid (Promega, Madison, USA), 100 ng of the indicated
pM1-CATS plasmid variants (expressing the wild type, phospho-
defective and phospho-mimic mutant proteins, respectively), together
with variable amounts of pcDNA-KIS (200–400 ng) or pcDNA-KISK54R
[27].
For the CATS-CALM/AF10 transactivation experiments, the cells
were co-transfected with 100 ng of the pGAL45tk-LUC reporter
plasmid, 50 ng of pRL-null co-reporter plasmid (Promega), 100 ng of
GAL4-DBD-CALM/AF10 [19] or GAL4-DBD expressing plasmid and
variable amounts of pSﬁExp-CATS-HA (100 ng, 200 ng, 400 ng) or
constant amounts of pSﬁExp-CATS-HA (200 ng) and pcDNA-KIS
(400 ng) in the case of KIS–CATS-CALM/AF10 experiments. DNA
amount was kept constant in each well by adding pcDNA empty vector
(Invitrogen, Carlsbad, CA, USA). Cells were harvested and assayed for
ﬁreﬂy and Renilla luciferase activities using a Dual-Luciferase Reporter
Assay System (Promega).2.10. Cell cycle synchronization
U2OS cells were synchronized by a double thymidine block as previ-
ously described [20]. After being released from cell cycle block cells
were collected at the indicated time points for protein extraction.
Synchronization was controlled by ﬂow cytometry analysis of the
DNA content and conﬁrmed by Western blot analysis using the indi-
cated cyclin antibodies (Santa Cruz Biotechnology).e 
I B
ected with plasmids expressing YFP-CATS and HA-KIS. (A) CATS colocalize with KIS in the
ine scan through the nucleus of the left cell from panel A. The image shows a cell with all
) signal intensities. Note that peak intensity of the CATS signal correlates with KIS staining.
1273L.F. Archangelo et al. / Biochimica et Biophysica Acta 1833 (2013) 1269–12793. Results
3.1. Identiﬁcation of the kinase KIS as a CATS interacting protein
In order to identify interactionpartners of CATSprotein,weperformed
a Y2H screen. The bait encoded the coding region of CATS isoform 1Async.
5 6
10 11
1
B
A
Fig. 3. Expression of KIS and CATS during the cell cycle. U2OS cells were synchronized by a
every 90 min (referred as samples 1–12). Synchronization was conﬁrmed by FACS and Wes
cell samples (1–12) analyzed by FACS (3B). Sample A is from a non-synchronized cell popula
of the U2OS cells collected at the different timepoints; samples 1–12 (Async: non-synchron(residues 1–238) fused to the GAL4-DBD. Among different prey clones
isolated we identiﬁed one coding for residues 33–419 of the Kinase
Interacting Stathmin KIS (UHMK1) (Fig. 1A). The interaction between
CATS and KIS was conﬁrmed by co-transforming the KIS and additional
10 prey plasmids and the CATS bait plasmid into yeast strain AH109. In-
teraction was assayed by cell growth on selective plates (Fig. 1B).2 3 4
7 8 9
12
double thymidine block. After thymidine release, cells were collected in 12 timepoints
tern blot using cycline antibodies. (A) Western blot with 50 μg extracts from the same
tion. Blots were stripped and reprobed with the indicated antibodies. (B) FACS analysis
ized sample).
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To conﬁrm that CATS and KIS interact and to determine which region
of CATS is responsible for this interaction, a glutathione S-transferaseA
B
Fig. 4. CATS is a substrate for KIS at serine 131. (A) Diagram representing the protein
phosphoproteomic studies. DB: destruction box motifs are depicted as orange boxes. Phospho
assay. Peptide sequences are represented enlarged. Plus (+) and minus (−) signs mean ph
were performed with constant amounts of kinase (recombinant GST-KIS) and two different c
full length (CATS FL), CATS N-terminal 1–143 (CATS NT), CATS N-terminal phosphorylation deﬁc
kinase used as negative control. (*) indicates the phosphorylated substrate. (C) Phosphorylation o
the average of normalized phosphate incorporationmeasurement from the reactions demonstrate(GST) pull-down assay was performed. To this end, CATS as well as its
deletion mutants (amino acids 1–238, 1–143, 136–187 and 188–248;
Fig. 1C) were expressed as GST fusion proteins in bacteria and
immobilized on glutathione beads. The beads were incubated withstructure of CATS and the phosphorylation sites within the protein as revealed by
rylation sites within the recombinant proteins used as substrates in the phosphorylation
osphorylated or not phosphorylated by KIS, respectively. (B) Phosphorylation reactions
oncentrations of each substrate (20 and 40 pmol). Substrates were GST-fusions of CATS
ient mutant (CATS NT S131A) and CATS C-terminal (188–248). No kinase: reactions without
f synthetic CATS peptides or positive controls (pCP9 and SF1) by KIS. (D) The bars represent
d in (C), a representative triplicate experiment is shown. Error bars show standard deviation.
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central portion (CATS 136–187) clearly retained the His-KIS protein
(Fig. 1D, upper panel lanes 3 and 5), while the N- and C-terminal por-
tions of CATS as well as GST did not (Fig. 1D, upper panel lanes 2, 4
and 6). These results conﬁrm the interaction between CATS and KIS
and map the interaction region to CATS amino acids 136–187.
To establish whether CATS interacts with KIS in vivo, HA-CATS
and GFP-KIS proteins were co-expressed in HEK293 cells and precip-
itated with anti-HA antibody, which detected the immunoprecipitated
CATS-HA proteins as shown in Fig. 1E, left panel, lower lanes 1, 2 and
4 (isoforms 1 and 2, respectively). The anti-KIS 3B12 antibody iden-
tiﬁed the co-precipitated GFP-KIS in the same lanes with anti-HA
immunoprecipitated proteins (Fig. 1E, left panel, upper lanes 1, 2
and 4), but not when isotype control was used (Fig. 1E, left panel,
upper lanes 3 and 5). The samewas observed in the reciprocal immu-
noprecipitation experiment, in which anti-GFP antibody efﬁciently
precipitated GFP-KIS (Fig. 1E, right panel, lower lanes 1, 2 and 4) and
the co-precipitated CATS-HA was detected with anti-HA (Fig. 1E, right
panel, upper lanes 1, 2 and 4) but not with the IgG control (Fig. 1E,
right panel, upper lanes 3 and 5).
To investigate whether the CATS–KIS interaction occurs between
the endogenous proteins, we examined the CALM/AF10 positive
monocytic cell line U937, as well as the lymphoblastic leukemia cell
line Jurkat. In both cell lines the CATS 2C4 antibody identiﬁed the
co-precipitated CATS in the lanes with anti-KIS immunoprecipitated
proteins (Fig. 1F, lane 1, left and right panels), but not with isotypeIgG immunoprecipitates (Fig. 1F, lane 2, left and right panels) demon-
strating that endogenous CATS and KIS form a complex in leuke-
mia cells.
3.3. CATS co-localizes with KIS in the nucleus
In order to learn more about the interaction between CATS and
KIS, we performed in vivo sub-cellular co-localization experiment
using overexpressed YFP-tagged CATS and HA-tagged KIS proteins.
Immunoﬂuorescence revealed co-localization of both proteins in the
nucleus (Fig. 2A). This was also obvious in a confocal line scan through
one of the nuclei where the intensity levels for YFP-CATS (green) and
HA-KIS (red) showed a similar distribution, in particular at the nucleolus
(Fig. 2B).
3.4. KIS and CATS expression during the cell cycle
We have previously shown that CATS is expressed in a cell
cycle-dependent fashion with higher levels present during S-, G2- and
G2/M-phases and lower levels of CATS in G1 [20]. Therefore we also
analyzed KIS expression during the cell cycle. Western blot analysis
of synchronized U2OS cells, revealed here that KIS expression also
varies throughout the cell cycle. However, different from CATS, KIS
expression peaks in the G1 phase and is lower during S phase
(Fig. 3). Thus KIS and CATS expression levels show opposite expression
patterns during cell cycle progression.
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Since we identiﬁed the kinase KIS as CATS interacting partner,
we searched the phosphoproteomic databases PhosphoSitePlus™
(http://www.phosphosite.org) and Phosida (http://www.phosida.com/)
[31] for phosphorylated CATS peptides. Combining the information avail-
able in these databases we identiﬁed 9 residues within CATS with
post-translational modiﬁcation (Fig. 4A) [31–35]. Most of these residues
except for S144 and S151 of CATS were described as phosphorylated in
a cell cycle dependent manner [31,33,34]. Only serine 131 of CATS
was located within the SGSP consensus sequence for KIS phosphoryla-
tion [36].A 
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Fig. 5. KIS enhances the transcriptional inhibitory function of CATS. HEK293 cells were co-t
change of the luciferase activity (normalized to the activity of the Renilla co-reporter) compa
activation: panels C and D). (A) Increasing amounts of KIS (200 ng and 400 ng) enhanced CA
(third and fourth bars). The same effect is observed when KIS is co-expressed with the pho
represent mean values of one representative out of two independent triplicate experiments.
repression of transcription (compare second and third bars). The kinase dead mutant
(DBD-CATSS131D) exerted the same transcriptional activity as the CATS wild type alone or c
The data represent mean values of one representative out of four independent triplicate expe
(C) CATS antagonize the transactivation capacity of CALM/AF10. GAL4-DBD-CALM/AF10 acti
about 4.2 fold compared to GAL4-DBD alone (second and ﬁrst bars). Increasing amounts of CA
to 1.7 fold in a dose-dependent manner. Increasing amounts of CATS in the absence of CALM/A
transactivation. The bars represent the average of normalizedﬁreﬂy luciferase values obtained f
dard deviation. * p=0.0002, ** p=0.0361, *** p=0.0074, **** p=0.0179 and ***** p=0.0018;
(compare third and fourth bars). Individual constructs expressing DBD-CALM/AF10, CATS and
nation. The bars represent the average of normalized ﬁreﬂy luciferase values obtained from ﬁ
** p=0.0096; Student's t-test.3.6. CATS serine 131 is the target of KIS phosphorylation
In order to investigatewhether CATS is a substrate for KIS phosphor-
ylation we performed an in vitro kinase assay. The substrate proteins
and peptides used in this assay are shown in Fig. 4A. Recombinant KIS
efﬁciently phosphorylated full length CATS and the N-terminal portion
of the CATS protein (aa 1–143) but not the C-terminal quarter of the
protein (aa 188–248) (Fig. 4B).
Tomap the KIS phosphorylation site in CATS, peptides containing all
known phospho-sites of the N-terminal portion of CATS as well as two
peptides containing mutations of the putative KIS target motif (S129A
and S131A) were tested for phosphorylation by KIS (Fig. 4C). Since0 
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ransfected with GAL4-tk-luciferase reporter plasmid and the constructs indicated. Fold
red to the background level of GAL4-DBD set as 1 (fold repression: panels A and B; fold
TS-mediated repression of transcription from 3- to 6-fold in a dose-dependent manner
sphorylation deﬁcient CATS mutant (DBD-CATSS131A) (ﬁfth and sixth bars). The data
Error bars show standard deviation. (B) KIS approximately doubles the CATS-mediated
(HKISK54R) has no effect on CATS function (fourth bar). Phosphomimetic CATS
o-transfected with the kinase dead mutant (compare ﬁfth with fourth and second bars).
riments. Error bars show standard deviation. * p=0.0348, ** p=0.0356; Student's t-test.
vates the reporter gene expression under the control of a GAL4-tk responsive promoter
TS (100 ng, 200 ng and 400 ng) reduced CALM/AF10-mediated transactivation from 4.2
F10 were used as a control for the speciﬁcity of CATS repression on CALM/AF10-mediated
rom two independent triplicate experimentsmeasured induplicates. Error bars showstan-
Student's t-test. (D) KIS enhances CATS effect over CALM/AF10-mediated transactivation
KIS alone were used as a control for the speciﬁcity of the effect observed upon its combi-
ve independent triplicate experiments. Error bars show standard deviation. * p=0.0091,
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S199 and S201 were not included in these assays. Recombinant KIS
did not phosphorylate peptide-S16 but peptides S129/S131 and S129A
(same amino acid sequence as peptide-S129/S131 but the serine at po-
sition 129 replaced by an alanine). The levels of phosphate incorpora-
tion were similar to the well-known KIS substrates pCP9 and SF1 [25]
(Fig. 4D). Phosphorylation was clearly reduced for peptide S131A
and the recombinant protein GST-CATS NT(1–143)S131A, in which
the serine 131 was replaced by an alanine (Fig. 4B, C and D). These
results demonstrate that KIS is a kinase for CATS and identify CATS
S131 as the unique target site for KIS phosphorylation.
3.7. KIS enhances the transcriptional repressor activity of CATS in a
GAL4-based transactivation assay
In our previous studieswe have shown that CATS acts as a transcrip-
tional inhibitorwhen fused to a GAL4-DBD [16]. Thereforewe used a re-
porter gene assay in order to determine the role of the KIS kinase on the
transcriptional inhibitory properties of CATS and to address whether
KIS phosphorylation of CATS on serine 131 might modulate this func-
tion of CATS. Co-expression of constant amounts of GAL4-DBD-CATS
and increasing amounts of KIS led to an enhanced inhibitory capacity
of CATS on the transactivation of the GAL4-tk-luciferase reporter by
up to 50%. This effect of KIS was observed for both wild-type CATS
and the CATS phospho-defective mutant (CATS S131A) but not when
a kinase dead mutant of KIS (KISK54R) was used (Fig. 5A). Moreover,
the CATS phospho-mimetic clone (CATSS131D) exerted the same tran-
scriptional activity like the wild type CATS (Fig. 5B). These results dem-
onstrate that KIS enhances the transcriptional repressor activity of
CATS, and this effect is independent of CATS phophorylation on
S131 but dependent on the kinase activity of KIS.
3.8. CATS and KIS antagonize the transactivation capacity of the leukemic
fusion protein CALM/AF10
We previously showed that CALM/AF10 can be retained in the
nucleus upon interaction with CATS [16] and that CALM/AF10 strongly
activates transcription when fused to a heterologous DNA-binding do-
main (GAL4-DBD) [19]. Thus, we wanted to investigate whether CATS
would affect the transactivation function of CALM/AF10. Coexpression
of constant amounts of GAL4-DBD-CALM/AF10 and increasing amounts
of CATS led to a decrease of the transactivation capacity of the CALM/
AF10. Higher amounts of CATS (400 ng) reduced CALM/AF10-mediated
transactivation of the GAL4-tk-luciferase reporter from 4.2- to 1.7-fold
(Fig. 5C).
We further investigated the effect of KIS on CATS-CALM/AF10 context
by introducing KIS in the aforementioned assay. Coexpression of
GAL4-DBD-CALM/AF10, CATS and KIS led to a lower CALM/AF10
transactivation, compared with when GAL4-DBD-CALM/AF10 was
coexpressed with CATS only. Moreover, KIS was also able to decrease
the transactivation capacity of the CALM/AF10 in the absence of CATS
coexpression (Fig. 5D).
4. Discussion
Phosphorylation regulates protein function, subcellular localization,
complex formation and protein stability. Therefore deﬁning and under-
standing kinase-substrate pairs is a major step towards understanding
cell signaling networks. Here we report the identiﬁcation of the Kinase
Interacting Stathmin KIS as a CATS interacting partner and identiﬁed
CATS S131 as the unique target site for KIS phosphorylation. Interest-
ingly, Olsen and colleagues have reported full phosphorylation of
CATS S131 during mitosis [34]. These ﬁndings suggest that KIS might
be the kinase phosphorylating CATS S131 during mitosis. Recently,
CATS has been reported as a mitotic regulator, that controls themetaphase to anaphase transition. In this context CATS is a substrate
of the APC/C complex degraded during mitotic exit [22].
Expression analysis on synchronized cells revealed increased
levels of KIS protein during the G1 and G2/M phases. The pattern of
KIS expression was a mirror image of the CATS levels, as KIS protein
increased exactly at the time when CATS levels started to decrease in
G2/M phase cells. Thus, it is tempting to speculate that KIS regulates
CATS stability during mitotic exit and consequently its role in
metaphase–anaphase transition. Further studies will be necessary to
address a possible role of KIS phosphorylation on CATS S131 on CATS
stability and cell division.
We showed that CATS and KIS colocalize in the nucleus and in the
nucleolus. We have previously reported the accumulation of CATS at
the nucleoli of cells arrested at the G1/S phase boundary [20]. Interest-
ingly, this is the time point when the highest levels of KIS are observed.
Since subcellular localization of proteins can be regulated through
phosphorylation events, one possibility is that CATS phosphorylation
on S131 controls CATS translocation to the nucleoli, and consequently
its function in the nucleoplasm.
Using a GAL4-based reporter gene assay we demonstrate that KIS
enhanced the repressor transcriptional activity of CATS. However, the
effect of KIS on CATSdoes not rely on CATS phosphorylation on S131 but
most likely on the protein–protein interaction between these proteins.
Nonetheless, the fact that the inactive form of KIS was unable to enhance
CATS transcriptional repression activity suggests that KIS kinase activity
is also required for this effect. Additionally, we show that CATS interferes
with the activation of transcription by CALM/AF10. Unexpectedly, KIS
alonewas also able tomodulate CALM/AF10 transactivation. Onepossible
explanation for this effect could be that it would bemediated throughKIS
interacting with endogenous CATS, known to be highly expressed in
the cells used for the reporter assay (HEK293). The fact that CATS
modulates the CALM/AF10 transactivation capacity suggests that
the CATS-CALM/AF10 (and possibly CATS-KIS) interaction is important
for leukemogenesis. However, it remains to be shown whether this
effect of CATS and KIS on CALM/AF10 transcriptional activity does
also play a role for direct cellular targets of CALM/AF10, which are
unknown so far.
At the present time, the mechanism by which CATS exerts its re-
pression effect on transcription is not known. Whether CATS simply
disturbs transcriptional activation complexes formed or whether it is
involved in the recruitment of transcriptional corepressors like histone
deacetylases or chromatin remodeling complexes is presently un-
known. There is some evidence that CATS might be able to recruit
chromatin remodeling factors. Zhao and colleagues have recently de-
scribed the interaction between CATS and components of the nucleo-
some remodeling and deacetylase (NuRD) complex [22]. The NuRD
complex, implicated in transcriptional regulation, is thought to have a
role in modifying the chromatin structure to initiate and maintain
gene repression [37].
In addition, CATSmay also play an important role in the regulation
of KIS activity and function. KIS is the only kinase described to have a
U2AF65 homologymotif (UHM). Through the UHMmotif, KIS is capable
of interacting with splicing factors such SF1 and SF3b155 [23]. Upon
interaction, KIS phosphorylates splicing factor SF1, which in turn en-
hances SF1 binding to U2AF65 and the 3′ splice site, an event known
to take place during the early steps of spliceosome assembly [25].
Thus, the interaction between CATS and KIS suggests a possible role
for CATS in RNA metabolism. This hypothesis is further supported
by the identiﬁcation of the RNA binding protein, PCBP1 (hnRNPE1)
[38] as the most frequent CATS interacting protein in our Y2H screen
(Fig. 1B and data not shown) and the recently described interaction
between CATS (FAM64A) and ROD1, an RNA-binding protein in-
volved in non-sense mediated RNA decay [39].
The CATS–KIS interaction might be especially important in neurons.
Although KIS is ubiquitously expressed, higher levels are detected in the
nervous system, suggesting a particularly signiﬁcant role in this tissue
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is expressed at high levels in the central nervous system (CNV) of de-
veloping embryo [20]. Additionally, recent report by Satoh et al. has
described CATS as a newly identiﬁed cellular prion protein (PrPC)
interactor and suggest that CATS is as a neuronal protein that
co-expresses with PrPC [21]. The fact that both CATS and KIS share
similar expression pattern in the CNS implies a biological relevance
of this interaction in the CNS and possibly relationship to PrPC. In
this context it is noteworthy that PrPC interacts with synapsin I
[43], a strong substrate of KIS in vitro [36].
5. Conclusions
In summary, we provide evidence for a novel interaction between
CATS and the kinase KIS. Thus characterizing a novel kinase–substrate
pair, which is part of a complex signaling network. We propose that
KIS is a critical modulator of CATS function and that the CATS–KIS
interaction is important in controlling gene expression and possibly
leukemogenesis.
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